Return to Publications
February 2018
RWJBarnabas HealthRutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including clinical trials and novel therapeutics such as precision medicine and immunotherapy.
Salma Jabbour, MD

Big Ten Cancer Research Consortium Names Rutgers Cancer Institute's Salma Jabbour to Steering Committee

Rutgers Cancer Institute of New Jersey radiation oncologist Salma Jabbour, MD, was recently appointed as a Steering Committee member to the Big Ten Cancer Research Consortium (BTCRC). The BTCRC works with the cancer centers of universities in the Big Ten Conference to propel cancer research and treatment discoveries through collaborative clinical trial efforts. Dr. Jabbour, who has a subspecialty in lung and gastrointestinal cancers, is also a professor of medicine at Rutgers Robert Wood Johnson Medical School.

Dale Schaar, MD, PhD

Rutgers Cancer Institute Named a Center of Excellence in Myelodysplastic Syndromes

Rutgers Cancer Institute of New Jersey is now recognized as a Center of Excellence by the Myelodysplastic Syndromes (MDS) Foundation in the research, diagnosis and treatment of MDS disorders. Rutgers Cancer Institute hematologist/oncologist Dale Schaar, MD, PhD, who is also an associate professor of medicine at Rutgers Robert Wood Johnson Medical School, is the principal investigator of the program and notes Rutgers Cancer Institute is one of only two such centers in the state.


Using 'LOHGIC' to Assess Inherited Cancer Mutations

Investigators at Rutgers Cancer Institute of New Jersey have developed a statistical method to identify patients with potential inherited, germline alterations in tumor suppressor genes while estimating gene loss in cancer cells through targeted genome sequencing. The work, published in the January 19 online edition ofJCO Precision Oncology (doi: 10.1200/PO.17.00148), describes the therapeutic implications of inherited cancer mutations and highlights the ongoing collaboration between computational biologists and physician-scientists involved in the Precision Medicine Program at Rutgers Cancer Institute.

Eugenia Girda, MD

A Resolution for Good Cervical Health

While potentially deadly, cervical cancer is a preventable gynecologic malignancy. According to the American Cancer Society, there are 13,000 new cases of invasive cervical cancer leading to 4,100 cancer-related deaths each year in the United States. As Eugenia Girda, MD, FACOG, a gynecologic oncologist at Rutgers Cancer Institute of New Jersey and an assistant professor of obstetrics, gynecology and reproductive sciences at Rutgers Robert Wood Johnson Medical School tells us, many deaths can be prevented through regular Pap screenings or the Human Papilloma Virus (HPV) vaccine.